DBV Technologies to file VIASKIN Peanut Patch BLA in Q3 2026 after FDA feedback

DBV Technologies will submit its BLA for the VIASKIN Peanut Patch in children 4–7 after incorporating FDA feedback, targeting Q3 2026 filing.Key Highlights:Original SEC Filing: DBV Technologies S.A. [ DBVT ] - 8-K - Jun. 29, 2026This is an AI-powered summary. It may contain inaccuracies. Consider v…

DBV Technologies will submit its BLA for the VIASKIN Peanut Patch in children 4–7 after incorporating FDA feedback, targeting Q3 2026 filing.

Key Highlights:

DBV engaged in detailed, iterative discussions with the FDA to optimize BLA organization and formatting.
The FDA provided actionable CMC and biostatistics guidance and did not request additional data.
DBV will take extra time to incorporate feedback and now anticipates filing the BLA in Q3 2026.
Company will host a conference call and webcast on June 29 at 5:00pm ET to discuss the update.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.